3 result(s) displayed (1 - 3 of 3):

More deals ahead, says Glaxo CEO (from Corporate Dealmaker)

Andrew Witty, CEO of GlaxoSmithKline plc, said in an interview with Bloomberg that he's looking to fill GSK's pipeline with licensing deals and acquisitions. At present about a quarter of the company's come from products that originated outside the company. He'd like to raise the proportion to half in about...

Posted on January 9, 2009 3:21 PM

Pharma's flurry of small deals as 2008 winds down (from Corporate Dealmaker)

M&A in the drug world might be stalled, with Example No. 1 being Roche Holding AG's $44 billion bid for Genentech Inc., but the year is ending with a burst of licensing activity.   The week before Christmas, we reported in The Deal (subscription required) at least six deals that...

Posted on December 31, 2008 8:55 AM

Big Pharma bulks up on biotech acquisitions (from Corporate Dealmaker)

Big Pharma companies have been racing to acquire smaller biotech companies to bulk up on technology as they face patent losses on top-selling drugs. Here are some of the latest deals: Sanofi-Aventis SA agreed to buy British vaccine maker Acambis plc for £276 million ($547.8 million) in order to secure...

Posted on July 25, 2008 4:49 PM